贝伐珠单抗联合靶向药物治疗表皮生长因子受体突变型非小细胞肺癌的临床疗效  

Clinical efficacy of bevacizumab combined with targeted therapy in epidermal growth factor receptor mutant non-small cell lung cancer

作　　者：赵秋红[1] 闫春良[1] 任冠军[1] ZHAO Qiuhong;YAN Chunliang;REN Guanjun(Department of Respiratory Medicine,Beijing General Aerospace Hospital,Beijing 100076,China)

机构地区：[1]北京航天总医院呼吸内科,北京1000760

出　　处：《癌症进展》2020年第14期1474-1476,1500,共4页Oncology Progress

摘　　要：目的探讨贝伐珠单抗联合靶向药物治疗表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)的临床疗效。方法根据治疗方法的不同将150例EGFR突变型NSCLC患者分为观察组和对照组,每组75例。观察组患者采用贝伐珠单抗联合盐酸埃克替尼片治疗,对照组患者仅采用盐酸埃克替尼片治疗。观察两组患者的临床疗效、生存情况及不良反应,采用生活质量综合评定问卷-74(GQOL-74)评价两组患者的生活质量。结果观察组患者的疾病控制率(DCR)为90.67%,明显高于对照组的69.33%,差异有统计学意义(P﹤0.01);观察组患者的治疗有效率(RR)为65.33%,明显高于对照组的41.33%,差异有统计学意义(P﹤0.01)。随访1~15个月,观察组患者的中位生存时间为11个月(95%CI:7.714~14.286),对照组患者的中位生存时间为8个月(95%CI:6.907~9.903);观察组患者的生存情况优于对照组,差异有统计学意义(P﹤0.05)。治疗后,观察组患者GQOL-74各维度评分均明显高于对照组,差异均有统计学意义(P﹤0.01)。治疗期间,观察组患者恶心、呕吐、口腔溃疡、血液学毒性的发生率均低于对照组,差异均有统计学意义(P﹤0.05)。结论与单独靶向治疗相比,贝伐珠单抗联合靶向治疗可提高EGFR突变型NSCLC患者的临床疗效,提高患者的短期生存率,降低不良反应,改善患者的生活质量。Objective To investigate the clinical efficacy of bevacizumab combined with targeted therapy for epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC).Method 150 patients with EGFR mutant NSCLC were divided into observation group(n=75)and control group(n=75)according to different treatment methods.The observation group was treated with bevacizumab combined with icotinib tablets,and the control group was treated with icotinib tablets.The clinical efficacy,survival and adverse reactions of the two groups were observed.The quality of life of the two groups was evaluated by the generic quality of life inventory-74(GQOL-74).Result The disease control rate(DCR)of the observation group was 90.67%,which was significantly higher than 69.33%of the control group(P<0.01).The response rate(RR)of the observation group was 65.33%,which was significantly higher than 41.33%of the control group(P<0.01).Following up for 1-15 months,the median survival time of the observation group was 11 months(95%CI:7.714-14.286)and that of the control group was 8 months(95%CI:6.907-9.903).The survival of the observation group was better than that of the control group,the difference was statistically significant(P<0.05).After treatment,the scores of GQOL-74 in the observation group were significantly higher than those in the control group(P<0.01).During the treatment,the incidence of nausea,vomiting,oral ulcer and hematological toxicity in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Compared with single targeted therapy,bevacizumab combined with targeted therapy can improve the efficacy for EGFR mutant NSCLC,improve short-term survival rate,reduce adverse reactions and improve the quality of life of the patients.

关 键 词：贝伐珠单抗 靶向治疗 表皮生长因子受体突变型 非小细胞肺癌 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]